ACIU Historical Income Statement

ACIU Stock

USD 3.40 0.01 0.29%

Historical analysis of AC Immune income statement accounts such as Selling General Administrative of 8.3 M, Total Revenue of 20 M or Cost Of Revenue of 45.8 M can show how well AC Immune performed in making a profits. Evaluating AC Immune income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of AC Immune's future profits or losses.

Cash Flow Balance Sheet Income Statement

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining AC Immune latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether AC Immune is a good buy for the upcoming year.

Net Income Gross Profit

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AC Immune. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

For more information on how to buy ACIU Stock please use our How to Invest in AC Immune guide.

About ACIU Income Statement Analysis

AC Immune Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to AC Immune shareholders. The income statement also shows ACIU investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

AC Immune Income Statement Chart

At this time, AC Immune's Total Revenue is comparatively stable compared to the past year. Interest Income is likely to gain to about 1.2 M in 2024, despite the fact that Gross Profit is likely to grow to (37.8 M).

Selling General Administrative Total Revenue Cost Of Revenue Total Operating Expenses Non Operating Income Net Other Net Interest Income

Total Revenue

Total revenue comprises all receipts AC Immune generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Cost Of Revenue

Cost of Revenue is found on AC Immune income statement and represents the costs associated with goods and services AC Immune provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.

Total Operating Expenses

The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.

Net Interest Income

The difference between the revenue generated from a bank's interest-bearing assets and the expenses associated with paying its interest-bearing liabilities.

Most accounts from AC Immune's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into AC Immune current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AC Immune. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

For more information on how to buy ACIU Stock please use our How to Invest in AC Immune guide.At this time, AC Immune's Total Revenue is comparatively stable compared to the past year. Interest Income is likely to gain to about 1.2 M in 2024, despite the fact that Gross Profit is likely to grow to (37.8 M).

	2021	2022	2023	2024 (projected)
Total Operating Expenses	79.0M	74.8M	13.8M	13.1M
Cost Of Revenue	62.3M	60.3M	54.6M	45.8M

Total Operating Expenses Cost Of Revenue

AC Immune income statement Correlations

	Interest Expense	Selling General Administrative	Total Revenue	Gross Profit	Operating Income	Net Income From Continuing Ops	Ebit	Cost Of Revenue	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Depreciation And Amortization	Other Operating Expenses	Research Development	Ebitda	Interest Income	Net Interest Income	Reconciled Depreciation
Interest Expense		0.43	0.81	0.3	0.27	0.29	0.27	0.45	0.55	0.29	0.22	0.29	0.33	0.52	0.5	0.48	0.17	-0.04	-0.46	0.41
Selling General Administrative	0.43		0.0	-0.58	-0.67	-0.67	-0.67	0.93	0.73	-0.67	0.04	-0.67	-0.15	0.95	0.95	0.96	-0.75	-0.06	-0.54	0.92
Total Revenue	0.81	0.0		0.69	0.71	0.71	0.7	0.03	0.13	0.71	0.01	0.71	0.52	0.15	0.09	0.06	0.57	-0.26	-0.43	0.02
Gross Profit	0.3	-0.58	0.69		0.91	0.9	0.91	-0.49	-0.24	0.9	-0.15	0.9	0.5	-0.53	-0.51	-0.54	0.82	-0.36	-0.13	-0.66
Operating Income	0.27	-0.67	0.71	0.91		1.0	1.0	-0.66	-0.39	1.0	-0.05	1.0	0.49	-0.55	-0.64	-0.66	0.97	-0.23	0.02	-0.65
Net Income From Continuing Ops	0.29	-0.67	0.71	0.9	1.0		1.0	-0.67	-0.38	1.0	0.01	1.0	0.52	-0.55	-0.63	-0.65	0.97	-0.19	0.06	-0.64
Ebit	0.27	-0.67	0.7	0.91	1.0	1.0		-0.67	-0.4	1.0	-0.04	1.0	0.51	-0.56	-0.64	-0.66	0.97	-0.23	0.04	-0.66
Cost Of Revenue	0.45	0.93	0.03	-0.49	-0.66	-0.67	-0.67		0.74	-0.67	-0.04	-0.67	-0.27	0.91	0.98	0.98	-0.77	0.02	-0.55	0.87
Total Operating Expenses	0.55	0.73	0.13	-0.24	-0.39	-0.38	-0.4	0.74		-0.38	0.22	-0.38	-0.02	0.64	0.74	0.73	-0.47	0.07	-0.35	0.57
Income Before Tax	0.29	-0.67	0.71	0.9	1.0	1.0	1.0	-0.67	-0.38		0.01	1.0	0.52	-0.55	-0.63	-0.65	0.97	-0.19	0.06	-0.64
Total Other Income Expense Net	0.22	0.04	0.01	-0.15	-0.05	0.01	-0.04	-0.04	0.22	0.01		0.01	0.42	0.08	0.1	0.11	-0.05	0.68	0.64	0.22
Net Income	0.29	-0.67	0.71	0.9	1.0	1.0	1.0	-0.67	-0.38	1.0	0.01		0.52	-0.55	-0.63	-0.65	0.97	-0.19	0.06	-0.64
Income Tax Expense	0.33	-0.15	0.52	0.5	0.49	0.52	0.51	-0.27	-0.02	0.52	0.42	0.52		-0.15	-0.13	-0.15	0.41	-0.19	0.07	-0.17
Depreciation And Amortization	0.52	0.95	0.15	-0.53	-0.55	-0.55	-0.56	0.91	0.64	-0.55	0.08	-0.55	-0.15		0.95	0.96	-0.64	0.02	-0.52	0.97
Other Operating Expenses	0.5	0.95	0.09	-0.51	-0.64	-0.63	-0.64	0.98	0.74	-0.63	0.1	-0.63	-0.13	0.95		1.0	-0.74	0.04	-0.51	0.93
Research Development	0.48	0.96	0.06	-0.54	-0.66	-0.65	-0.66	0.98	0.73	-0.65	0.11	-0.65	-0.15	0.96	1.0		-0.76	0.05	-0.49	0.94
Ebitda	0.17	-0.75	0.57	0.82	0.97	0.97	0.97	-0.77	-0.47	0.97	-0.05	0.97	0.41	-0.64	-0.74	-0.76		-0.18	0.13	-0.72
Interest Income	-0.04	-0.06	-0.26	-0.36	-0.23	-0.19	-0.23	0.02	0.07	-0.19	0.68	-0.19	-0.19	0.02	0.04	0.05	-0.18		0.75	0.2
Net Interest Income	-0.46	-0.54	-0.43	-0.13	0.02	0.06	0.04	-0.55	-0.35	0.06	0.64	0.06	0.07	-0.52	-0.51	-0.49	0.13	0.75		-0.33
Reconciled Depreciation	0.41	0.92	0.02	-0.66	-0.65	-0.64	-0.66	0.87	0.57	-0.64	0.22	-0.64	-0.17	0.97	0.93	0.94	-0.72	0.2	-0.33

Click cells to compare fundamentals

AC Immune Account Relationship Matchups

AC Immune income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Interest Expense	1.9M	184K	581K	355K	176K	167.2K
Selling General Administrative	9.4M	11.1M	10.9M	15.8M	10.6M	8.3M
Total Revenue	111.0M	15.4M	944K	3.9M	14.8M	20.0M
Gross Profit	60.6M	(44.1M)	(62.3M)	(56.4M)	(39.8M)	(37.8M)
Operating Income	44.5M	(61.3M)	(79.0M)	(70.8M)	(53.6M)	(50.9M)
Net Income From Continuing Ops	45.4M	(61.9M)	(73.0M)	(70.8M)	(54.2M)	(51.5M)
Ebit	44.5M	(63.2M)	(79.0M)	(71.4M)	(54.0M)	(51.3M)
Cost Of Revenue	50.4M	59.5M	62.3M	60.3M	54.6M	45.8M
Total Operating Expenses	66.5M	76.7M	79.0M	74.8M	13.8M	13.1M
Income Before Tax	45.4M	(61.9M)	(73.0M)	(70.7M)	(54.2M)	(51.5M)
Total Other Income Expense Net	906K	(661K)	6.0M	107K	(599K)	(569.1K)
Net Income Applicable To Common Shares	45.4M	(61.9M)	(73.0M)	(70.8M)	(63.7M)	(60.5M)
Net Income	45.4M	(62.1M)	(73.0M)	(70.8M)	(54.2M)	(51.5M)
Income Tax Expense	1.9M	184K	3K	13K	10K	9.5K
Depreciation And Amortization	2.0M	2.0M	1.9M	2.4M	2.2M	1.4M
Other Operating Expenses	66.5M	76.7M	79.0M	74.8M	68.4M	59.2M
Research Development	50.4M	59.5M	62.3M	60.3M	54.6M	46.5M
Ebitda	46.5M	(61.3M)	(77.1M)	(69.1M)	(51.8M)	(49.2M)
Interest Income	304K	78K	6.5M	69K	1.0M	1.2M
Net Interest Income	(1.6M)	(106K)	5.9M	(286K)	868K	1.1M
Reconciled Depreciation	1.7M	2.0M	2.4M	2.4M	2.2M	1.9M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for ACIU Stock Analysis

When running AC Immune's price analysis, check to measure AC Immune's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AC Immune is operating at the current time. Most of AC Immune's value examination focuses on studying past and present price action to predict the probability of AC Immune's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AC Immune's price. Additionally, you may evaluate how the addition of AC Immune to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

ACIU Historical Income Statement

About ACIU Income Statement Analysis

AC Immune Income Statement Chart

Total Revenue

Cost Of Revenue

Total Operating Expenses

Net Interest Income

AC Immune income statement Correlations

AC Immune Account Relationship Matchups

High Positive Relationship

High Negative Relationship

AC Immune income statement Accounts

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for ACIU Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Net Income From Continuing Ops	+ 1.0	Operating Income
Ebit	+ 1.0	Operating Income
Income Before Tax	+ 1.0	Operating Income
Net Income	+ 1.0	Operating Income
Ebit	+ 1.0	Net Income From Continuing Ops
Income Before Tax	+ 1.0	Net Income From Continuing Ops

Ebitda	- 0.77	Cost Of Revenue
Ebitda	- 0.76	Research Development
Ebitda	- 0.75	Selling General Administrative
Ebitda	- 0.74	Other Operating Expenses
Reconciled Depreciation	- 0.72	Ebitda
Net Income	- 0.67	Cost Of Revenue